<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1816-8949</journal-id>
<journal-title><![CDATA[Anales de la Facultad de Ciencias Médicas (Asunción)]]></journal-title>
<abbrev-journal-title><![CDATA[An. Fac. Cienc. Méd. (Asunción)]]></abbrev-journal-title>
<issn>1816-8949</issn>
<publisher>
<publisher-name><![CDATA[EFACIM. Editorial de la Facultad de Ciencias Médicas - Universidad Nacional de Asunción]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1816-89492024000300102</article-id>
<article-id pub-id-type="doi">10.18004/anales/2024.057.03.102</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa]]></article-title>
<article-title xml:lang="en"><![CDATA[Semaglutide: From Fashion to Scientific Evidence. About a Narrative Review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[Elvio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jara]]></surname>
<given-names><![CDATA[Elias]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jara]]></surname>
<given-names><![CDATA[Jessica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arce]]></surname>
<given-names><![CDATA[Maura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[Ana Iris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Canata]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Asunción Facultad de Ciencias Médicas, Hospital de Clínicas Segunda Cátedra de Clínica Médica]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Asunción Facultad de Ciencias Médicas, Hospital de Clínicas Departamento de Endocrinología y Metabolismo]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Ministerio de Salud Pública y Bienestar Social del Paraguay Hospital Acosta Ñu Departamento de Endocrinología Pediátrica]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>57</volume>
<numero>3</numero>
<fpage>102</fpage>
<lpage>109</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S1816-89492024000300102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S1816-89492024000300102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S1816-89492024000300102&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  La obesidad es una condición que afecta a una gran proporción de la población mundial y se asocia con problemas de salud graves. En los últimos años, el uso de semaglutide, inicialmente desarrollado para el tratamiento de la diabetes tipo 2, ha demostrado eficacia no solo en el control glucémico, sino también en la pérdida de peso. Este medicamento, un análogo del GLP-1, actúa reduciendo el apetito y prolongando la saciedad, además de aportar beneficios en la función cardiovascular y renal, e incluso mejorar la apnea obstructiva del sueño. La semaglutide ha sido aprobada para el tratamiento de la diabetes y la obesidad tanto en adultos como en adolescentes, y está disponible en formatos subcutáneo y oral. A pesar de sus beneficios, se han reportado efectos secundarios, como náuseas y un potencial riesgo de cáncer tiroideo y retinopatía diabética, los cuales deben ser considerados y monitoreados. El desarrollo de nuevos agonistas duales y triples, y la combinación de semaglutide con insulina semanal, representan futuros prometedores en el tratamiento de la obesidad y la diabetes, mejorando las opciones terapéuticas para estas condiciones crónicas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Obesity is a condition affecting a large proportion of the global population, linked to significant health issues. In recent years, semaglutide, originally developed for type 2 diabetes treatment, has proven effective not only for glycemic control but also for weight loss. This GLP-1 analog reduces appetite and prolongs satiety, while also providing cardiovascular and renal benefits, and even improving obstructive sleep apnea. Semaglutide has been approved for diabetes and obesity management in adults and adolescents and is available in both subcutaneous and oral formulations. Despite its benefits, some side effects have been reported, including nausea and potential risks of thyroid cancer and diabetic retinopathy, which should be monitored. The development of new dual and triple agonists, as well as the combination of semaglutide with weekly insulin, represent promising future advances in treating obesity and diabetes, enhancing therapeutic options for these chronic conditions.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Obesidad]]></kwd>
<kwd lng="es"><![CDATA[Semaglutide]]></kwd>
<kwd lng="es"><![CDATA[Diabetes tipo 2]]></kwd>
<kwd lng="es"><![CDATA[GLP-1]]></kwd>
<kwd lng="es"><![CDATA[Pérdida de peso]]></kwd>
<kwd lng="es"><![CDATA[Riesgo cardiovascular]]></kwd>
<kwd lng="es"><![CDATA[Apnea del sueño.]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
<kwd lng="en"><![CDATA[Semaglutide]]></kwd>
<kwd lng="en"><![CDATA[Type 2 diabetes]]></kwd>
<kwd lng="en"><![CDATA[GLP-1]]></kwd>
<kwd lng="en"><![CDATA[Weight loss]]></kwd>
<kwd lng="en"><![CDATA[Cardiovascular risk]]></kwd>
<kwd lng="en"><![CDATA[Sleep apnea.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>World Obesity Federation</collab>
<source><![CDATA[World Obesity Atlas 2023]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zunz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[LaBarre]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contributions a l&#8217;etude des variation physiologiques de la secretion interne de pancreas: relations entre les secretions externe et interne du pancreas]]></article-title>
<source><![CDATA[Archs Int Physiol Biochim]]></source>
<year>1929</year>
<volume>31</volume>
<page-range>20-44</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gastric inhibitory polypeptide]]></article-title>
<source><![CDATA[Monogr Endocrinol]]></source>
<year>1982</year>
<volume>24</volume>
<numero>III-XI</numero>
<issue>III-XI</issue>
<page-range>1-88</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holst]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Orskov]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal intestine]]></article-title>
<source><![CDATA[FEBS Lett]]></source>
<year>1987</year>
<volume>211</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>169-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mentlein]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gallwitz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dipeptidyl peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, histidine peptide methionine, and is responsible for their degradation in human serum]]></article-title>
<source><![CDATA[Eur J Biochem]]></source>
<year>1993</year>
<volume>214</volume>
<page-range>829-35</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bloch]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Schäffer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide]]></article-title>
<source><![CDATA[J Med Chem]]></source>
<year>2015</year>
<volume>58</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>7370-80</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhillon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide: first global approval]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2018</year>
<volume>78</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>275-84</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Harashima]]></surname>
<given-names><![CDATA[S-I]]></given-names>
</name>
<name>
<surname><![CDATA[Tsoukas]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a phase 3a, double-blind, randomized, placebo-controlled, multinational, multicenter clinical trial]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2017</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>251-60</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahrén]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Masmiquel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an addition to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a randomized, double-blind, phase 3a trial over 56 weeks]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2017</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>341-54</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmann]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Capehorn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Charpentier]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a randomized, open-label clinical trial over 56 weeks]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2018</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>258-66</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aroda]]></surname>
<given-names><![CDATA[VR]]></given-names>
</name>
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Cariou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as an addition to metformin (with or without sulfonylureas) in naïve insulin patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicenter, multinational, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2017</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>355-66</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodbard]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Lingvay]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2018</year>
<volume>103</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2291-301</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pratley]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Aroda]]></surname>
<given-names><![CDATA[VR]]></given-names>
</name>
<name>
<surname><![CDATA[Lingvay]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide Versus Once-Weekly Dulaglutide in Patients with Type 2 Diabetes (SUSTAIN 7): A Randomized, Open-Label, Phase 3b Trial]]></article-title>
<source><![CDATA[Lancet Diabetes. Endocrinol]]></source>
<year>2018</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>275-86</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Calanna]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP 1 to 5 trials]]></article-title>
<source><![CDATA[Obesity (Silver Spring)]]></source>
<year>2020</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1050-61</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Wegovy (semaglutide): A New Weight Loss Drug in Chronic Weight Management]]></article-title>
<source><![CDATA[J Investig Med]]></source>
<year>2022</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Færch]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jeppesen]]></surname>
<given-names><![CDATA[OK]]></given-names>
</name>
<name>
<surname><![CDATA[Pakseresht]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Perreault]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide 2.4 mg once weekly in adults who are overweight or obese and have type 2 diabetes (STEP 2): a randomized, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10278</numero>
<issue>10278</issue>
<page-range>971-84</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weghuber]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Barrientos-Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide once a week in adolescents with obesity]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>387</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2245-57</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivero-Martín]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Azcona-Sanjulián]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Bahíllo Curieses]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on the medical treatment of overweight and obesity in children and adolescents]]></article-title>
<source><![CDATA[Rev Esp Endocrinol Pediatr]]></source>
<year>2022</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>51-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Colhoun]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Lingvay]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Semaglutide on Cardiovascular Outcomes in Overweight or Obese People (SELECT): Rationale and Design]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2020</year>
<volume>229</volume>
<page-range>61-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marso]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Consoli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide and cardiovascular outcomes in patients with type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1834-44</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tuttle]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Rossing]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[JFE]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2024</year>
<volume>391</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>109-21</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bliddal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bays]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Czernichow]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Semaglutide once a week in people with obesity and osteoarthritis of the knee]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2024</year>
<volume>391</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1573-83</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Borradaile]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: The Sleep AHEAD study]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2009</year>
<volume>169</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1619-26</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zargar]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of the Available Evidence for Oral Semaglutide: A New Era in Diabetes Management with Peptides in Pill Form]]></article-title>
<source><![CDATA[Indian J Endocr Metab]]></source>
<year>2022</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>98-105</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bezin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gouverneur]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pénichon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mathieu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Garrel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hillaire-Buys]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GLP-1 receptor agonists and thyroid cancer risk]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2023</year>
<volume>46</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>384-90</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hathaway]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Hathaway]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of non-arteritic anterior ischemic optic neuropathy in patients prescribed semaglutide]]></article-title>
<source><![CDATA[JAMA Ophthalmol]]></source>
<year>2024</year>
<volume>142</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>732-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kapoor]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kolomeyer]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Stokkermans]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smiddy]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Berrocal]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Flynn Jr]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials]]></article-title>
<source><![CDATA[Survey of Ophthalmology]]></source>
<year>2023</year>
<volume>68</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1071-83</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety Issues with Glucagon-1 Peptide Receptor Agonists (Pancreatitis, Pancreatic Cancer, and Cholelithiasis): Data from Randomized Controlled Trials]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2017</year>
<volume>19</volume>
<page-range>1233-11241</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorgojo Martínez]]></surname>
<given-names><![CDATA[J.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Mezquita Raya]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Carretero Gómez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Cebrián Cuenca]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[de Torres Sánchez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones clínicas para manejar eventos adversos gastrointestinales en pacientes tratados con agonistas del receptor de GLP-1: Un consenso de expertos multidisciplinario]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2022</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>145</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Volkow]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Kaelber DC]]></surname>
<given-names><![CDATA[Xu R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of semaglutide with risk of suicidal ideation in a real-world cohort]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2024</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>168-76</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerem]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Stokar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of suicidal ideation or attempts in obese adolescents treated with GLP1 receptor agonists]]></article-title>
<source><![CDATA[JAMA Pediatr]]></source>
<year>2024</year>
<volume>178</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1307-15</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Marrs]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide for type 2 diabetes]]></article-title>
<source><![CDATA[Drugs Context]]></source>
<year>2023</year>
<volume>12</volume>
<page-range>2023-6-1</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seetharaman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IcoSema: Revealing the Future of Diabetes Management from a Clinical Pharmacology Perspective]]></article-title>
<source><![CDATA[J Basic Clin Physiol Pharmacol]]></source>
<year>2024</year>
<volume>35</volume>
<numero>4-5</numero>
<issue>4-5</issue>
<page-range>213-24</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Deenadayalan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Erichsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Knop]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
<name>
<surname><![CDATA[Lingvay]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Macura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of co-administration of once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicenter, randomized, double-blind, actively controlled, phase 2 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2023</year>
<volume>402</volume>
<numero>10403</numero>
<issue>10403</issue>
<page-range>720-30</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frías]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Manghi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Landó]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J of Med]]></source>
<year>2021</year>
<volume>385</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>503-15</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jastreboff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Frías]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gurbuz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retatrutide Triple Hormone Receptor Agonist for Obesity: A Phase 2 Trial]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2023</year>
<volume>389</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>514-26</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishver. A]]></surname>
<given-names><![CDATA[Riemann L]]></given-names>
</name>
</person-group>
<source><![CDATA[Rybelsus (semaglutida): usos, efectos secundarios y más]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
